Triple Negative Breast Cancer [clinicaltrials_resource:bced8d49df91eb538fcdf3d178723296]
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer [clinicaltrials:NCT00707707]A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer [clinicaltrials:NCT00813956]A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer [clinicaltrials:NCT00951054]Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors [clinicaltrials:NCT00998036]Triple Negative Breast Cancer Biomarker Study [clinicaltrials:NCT01111175]Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer [clinicaltrials:NCT01216111]clinicaltrials:NCT01276769Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients [clinicaltrials:NCT01276899]clinicaltrials:NCT01307891A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers [clinicaltrials:NCT01451632]Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment [clinicaltrials:NCT01520389]An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors [clinicaltrials:NCT01618136]A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer [clinicaltrials:NCT01639248]An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer [clinicaltrials:NCT01677455]clinicaltrials:NCT01745367clinicaltrials:NCT01770353cMet CAR RNA T Cells Targeting Breast Cancer [clinicaltrials:NCT01837602]clinicaltrials:NCT01918306NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer [clinicaltrials:NCT01931163]Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer [clinicaltrials:NCT01969032]clinicaltrials:NCT01982448clinicaltrials:NCT02000882clinicaltrials:NCT02012634clinicaltrials:NCT02032277Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes [clinicaltrials:NCT02225470]clinicaltrials:NCT02247037A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors [clinicaltrials:NCT02259114]Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy [clinicaltrials:NCT02348320]clinicaltrials:NCT02365662Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) [clinicaltrials:NCT02368691]clinicaltrials:NCT02404441Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy [clinicaltrials:NCT02427581]clinicaltrials:NCT02511847
condition [clinicaltrials_vocabulary:condition]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Triple Negative Breast Cancer [clinicaltrials_resource:bced8d49df91eb538fcdf3d178723296]
Bio2RDF identifier
bced8d49df91eb538fcdf3d178723296
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bced8d49df91eb538fcdf3d178723296
identifier
clinicaltrials_resource:bced8d49df91eb538fcdf3d178723296
title
Triple Negative Breast Cancer
@en
type
label
Triple Negative Breast Cancer [clinicaltrials_resource:bced8d49df91eb538fcdf3d178723296]
@en